EX-99.1
2
v467631_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Elite Pharmaceuticals Acquires Trimipramine
ANDA
Dr. Reddy's Laboratories to Provide
Marketing and Sales
Northvale, NJ - May 16, 2017: Elite
Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), today announced the acquisition of an approved
and currently marketed Abbreviated New Drug Application ("ANDA") for Trimipramine Maleate Capsules ("Trimipramine")
25, 50 and 100 mg, from Mikah Pharma, LLC ("Mikah"). Dr. Reddy's Laboratories, Inc. ("Dr. Reddy")
(BSE: 500124, NSE: DRREDDY, NYSE: RDY) will market and sell the Trimipramine products. Epic Pharma will manufacture the products
under current agreements with Mikah. Eilte will assume these agreements with the acquisition of the products. This agreement insures
the uninterrupted supply of generic Trimipramine. Trimipramine is a generic version of Surmontil®,
a
tricyclic antidepressant. Surmontil® and generic
Trimipramine have total US sales of approximately $2 million in 2016 according to IMS Health Data. The ANDA purchased by Elite
is currently the only marketed generic Trimipramine product.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty
pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse deterrent opioid products as well as
niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International.
Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and
the NDA for SequestOx™, for which it received the CRL from the FDA. Elite's lead pipeline products include abuse-deterrent
opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained
release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations
of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.
Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a
GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY,
NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products -
Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars
and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology,
pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA,
India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects,
if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press
release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation,
Elite's ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties,
inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance
or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by
these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval,
if at all, of SequestOx™ by the FDA, the steps Elite may take as a result of the CRL, and the actions the FDA require of
Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance.
These risks and other factors, including, without limitation, Elite's ability to obtain sufficient funding under the LPC
Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals
by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed
in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under
no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

EX - 99 . 1 2 v467631 _ ex99 - 1 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 Elite Pharmaceuticals Acquires Trimipramine ANDA Dr . Reddy 's Laboratories to Provide Marketing and Sales Northvale , NJ - May 16 , 2017 : Elite Pharmaceuticals , Inc . ( " Elite " or the " Company " ) ( OTCBB : ELTP ) , today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application ( " ANDA " ) for Trimipramine Maleate Capsules ( " Trimipramine " ) 25 , 50 and 100 mg , from Mikah Pharma , LLC ( " Mikah " ) . Dr . Reddy 's Laboratories , Inc . ( " Dr . Reddy " ) ( BSE : 500124 , NSE : DRREDDY , NYSE : RDY ) will market and sell the Trimipramine products . Epic Pharma will manufacture the products under current agreements with Mikah . Eilte will assume these agreements with the acquisition of the products . This agreement insures the uninterrupted supply of generic Trimipramine . Trimipramine is a generic version of Surmontil ® , a tricyclic antidepressant . Surmontil ® and generic Trimipramine have total US sales of approximately $ 2 million in 2016 according to IMS Health Data . The ANDA purchased by Elite is currently the only marketed generic Trimipramine product . About Elite Pharmaceuticals , Inc . Elite Pharmaceuticals , Inc . is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse deterrent opioid products as well as niche generic products . Elite specializes in oral sustained and controlled release drug products which have high barriers to entry . Elite owns generic and OTC products which have been licensed to TAGI Pharma , Epic Pharma and Valeant Pharmaceuticals International . Elite currently has eight commercial products being sold , additional approved products pending manufacturing site transfer and the NDA for SequestOx ™ , for which it received the CRL from the FDA . Elite 's lead pipeline products include abuse - deterrent opioids which utilize the Company ' s patented proprietary technology and a once - daily opioid . These products include sustained release oral formulations of opioids for the treatment of chronic pain . These formulations are intended to address two major limitations of existing oral opioids : the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse . Elite also provides contract manufacturing for Ascend Laboratories ( a subsidiary of Alkem Laboratories Ltd . ) . Elite operates a GMP and DEA registered facility for research , development , and manufacturing located in Northvale , NJ . Learn more at www.elitepharma.com . About Dr . Reddy 's Dr . Reddy 's Laboratories Ltd . ( BSE : 500124 , NSE : DRREDDY , NYSE : RDY ) is an integrated pharmaceutical company , committed to providing affordable and innovative medicines for healthier lives . Through its three businesses - Pharmaceutical Services & Active Ingredients , Global Generics and Proprietary Products - Dr . Reddy 's offers a portfolio of products and services including APIs , custom pharmaceutical services , generics , biosimilars and differentiated formulations . Our major therapeutic areas of focus are gastrointestinal , cardiovascular , diabetology , oncology , pain management and dermatology . Dr . Reddy 's operates in markets across the globe . Our major markets include - USA , India , Russia & CIS countries , and Europe . For more information , log on to : www.drreddys.com . This press release contains " forward - looking statements " within the meaning of the Private Securities Litigation Reform Act of 1995 . Including those related to the effects , if any , on future results , performance or other expectations that may have some correlation to the subject matter of this press release , readers are cautioned that such forward - looking statements involve risks and uncertainties including , without limitation , Elite 's ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process , delays , uncertainties , inability to obtain necessary ingredients and other factors not under the control of Elite , which may cause actual results , performance or achievements of Elite to be materially different from the results , performance or other expectations that may be implied by these forward - looking statements . These forward - looking statements may include statements regarding the expected timing of approval , if at all , of SequestOx ™ by the FDA , the steps Elite may take as a result of the CRL , and the actions the FDA require of Elite in order to obtain approval of the NDA . These forward - looking statements are not guarantees of future action or performance . These risks and other factors , including , without limitation , Elite 's ability to obtain sufficient funding under the LPC Agreement or from other sources , the timing or results of pending and future clinical trials , regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses , are discussed in Elite 's filings with the Securities and Exchange Commission , including its reports on forms 10 - K , 10 - Q and 8 - K . Elite is under no obligation to update or alter its forward - looking statements , whether as a result of new information , future events or otherwise . Contact : For Elite Pharmaceuticals , Inc . Dianne Will , Investor Relations , 518 - 398 - 6222 Dianne@elitepharma.com www.elitepharma.com